Spss ver 12.0 for windows

Results are expressed as mean±standard deviation. Statistical analysis was performed using SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA). One-way analysis of variance, the Kruskal-Wallis rank test, or the Fisher exact test was performed to analyze the significance of differences between groups. A p-value of <0.05 was considered to indicate a statistically significant difference.

The chi-square test and Fisher exact test were used to compare the clinicopathological factors between the groups according to the development of metachronous gastric neoplasms. The t-test was used for noncategorical variables in the intergroup comparisons of clinicopathological characteristics. The Wilcoxon signed-rank test and Mann-Whitney U-test were used for evaluating immunohistochemical expression levels. The metachronous and nonmetachronous groups were matched according to age and sex by using propensity score matching at a ratio 1o:f3. Statistical significance was set at P<0.05. All statistical analyses were performed by using SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA).

The Kruskal-Wallis test and Mann-Whitney test were employed to evaluate the differences in IL-1α and LPO levels among the groups divided by the smoking habit, KAGS, and lesion distribution. Pearson's correlation test was also employed to assess the relationships between LPO and IL-1α. Statistical significance was defined by a p-value<0.05. Statistical analyses were conducted using SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA).

SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Statistical significance was analyzed using the Mann-Whitney U-test and p<0.05 were considered to indicate statistical significance.

Statistical analyses were performed using SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA). Data are presented as means±standard error of the means. Student t-test was used for comparison of continuous variables. The percentage change in pain (VAS for leg and back pain) and percentage change in disability (ODI) were calculated according to the following equation: percentage change=(postoperative VAS or ODI–preoperative VAS or ODI)/preoperative VAS or ODI×100, where the postoperative values were those obtained at the 2-year follow-up. All p-values of <0.05 were accepted as indicating statistical significance.

Primary endpoint of this retrospective study was OS and PFS rates. Secondary endpoints were prognostic factors, treatment response, and treatment toxicities. OS time was counted from the date of diagnosis to death or the last follow-up date in survivors. Progression free survival time was from the date of completion of CCRT to the date of progression. Survival curves and local control rates were achieved using the Kaplan-Meier method and the differences were evaluated by log-rank test. Univariate and multivariate analyses as well as Cox proportional hazards models were used to assess prognostic factors. Treatment response was assessed by comparing abdomen CTs taken before and after radiotherapy using Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 [11 (link)]. To identify the relationship between toxicities and radiation dose, Pearson correlation analysis was used. When interpreting the results, p-values less than 0.05 were considered significant. All data were computed and analyzed with SPSS ver. 12.0 for Windows (SPSS Inc., Chicago, IL, USA).